1. Home
  2. NKX vs DCTH Comparison

NKX vs DCTH Comparison

Compare NKX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

SELL

Current Price

$11.23

Market Cap

643.9M

Sector

Finance

ML Signal

SELL

DCTH

Delcath Systems Inc.

SELL

Current Price

$21.73

Market Cap

578.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NKX
DCTH
Founded
2002
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
643.9M
578.4M
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
NKX
DCTH
Price
$11.23
$21.73
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $28.60
AVG Volume (30 Days)
281.7K
★ 606.1K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 4.37%
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.21
Revenue
N/A
N/A
Revenue This Year
N/A
$36.66
Revenue Next Year
N/A
$20.12
P/E Ratio
★ N/A
$104.33
Revenue Growth
N/A
N/A
52 Week Low
$10.30
$8.12
52 Week High
$13.20
$22.33

Technical Indicators

Market Signals
Indicator
NKX
DCTH
Relative Strength Index (RSI) 55.72 81.77
Support Level $10.30 $10.76
Resistance Level $11.30 N/A
Average True Range (ATR) 0.16 0.97
MACD 0.04 0.82
Stochastic Oscillator 69.72 95.01

Price Performance

Historical Comparison
NKX
DCTH

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal income tax, the federal alternative minimum tax applicable to individuals, and California income tax, and to enhance portfolio value relative to the municipal bond market. Under normal circumstances, the majority of the company's managed assets are invested in municipal securities and other related investments, the income from which is exempt from the federal alternative minimum tax applicable to individuals at the time of purchase.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: